Biomed Industries, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 31

Phase 11

By Therapeutic Area

top 1

Metabolic & Endocrine

150%

R&D Momentum

18/100

Pipeline Velocity

6/100

Trial Completion Rate

100/100

Pipeline Concentration

50/100

Pipeline Freshness

65/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Key Events

Oct 30, 2025TrialTo Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Mar 15, 2025TrialSafety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Jul 25, 2024FDALeqselvi — LEQSELVI

Jul 19, 2024TrialPhase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition

May 6, 2024TrialPhase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Mar 15, 2024TrialTo Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

Nov 17, 2022FDALuminal — SEZABY

Jun 15, 2022TrialNA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

4 more events

Nov 1, 2020TrialA Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Sep 15, 2020TrialSafety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

Nov 6, 2018FDALexette — BRYHALI

Sep 15, 2018TrialA Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

15 patent groups across drugs · Source: FDA Orange Book

DrugExpires

LevulanFeb 7, 2028 Lexette3 patentsNov 2, 2031 LexetteJun 19, 2033 Levulan3 patentsOct 13, 2036 Lexette2 patentsNov 30, 2036 LevulanJan 17, 2037 Leqselvi2 patentsMay 4, 2037 LexetteMay 30, 2037

7 more

Levulan6 patentsJan 12, 2038 LevulanOct 15, 2040 LeqselviMay 21, 2041 Luminal2 patentsApr 7, 2042 LeqselviAug 11, 2042 LevulanDec 8, 2043 Leqselvi2 patentsMay 10, 2044

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

NA-931Phase 1

Unknown / Other

Rett Syndrome

BionetidePhase 3

Regulatory

Regulatory Timeline

19822 events

FDAJan 1

Lac-Hydrin — AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

Application NDA006580 (NDA)

FDAJan 1

Lac-Hydrin — AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

Application NDA006580 (NDA)

19852 events

FDAApr 24

Lac-Hydrin — LAC-HYDRIN

Application NDA019155 (NDA)

FDAApr 24

Lac-Hydrin — LAC-HYDRIN

Application NDA019155 (NDA)

19902 events

FDADec 27

Lexette — ULTRAVATE

Application NDA019967 (NDA)

FDADec 17

Lexette — ULTRAVATE

Application NDA019968 (NDA)

19932 events

FDASep 17

Flumadine — FLUMADINE

Application NDA019650 (NDA)

FDASep 17

Flumadine — FLUMADINE

Application NDA019649 (NDA)

19962 events

FDAAug 29

Lac-Hydrin — LAC-HYDRIN

Application NDA020508 (NDA)

FDAAug 29

Lac-Hydrin — LAC-HYDRIN

Application NDA020508 (NDA)

19991 event

FDADec 3

Levulan — LEVULAN

Application NDA020965 (NDA)

20051 event

FDAAug 12

Qualaquin — QUALAQUIN

Application NDA021799 (NDA)

20151 event

FDANov 6

Lexette — ULTRAVATE

Application NDA208183 (NDA)

20161 event

FDAMay 10

Levulan — AMELUZ

Application NDA208081 (NDA)

20171 event

FDAJun 6

Levulan — GLEOLAN

Application NDA208630 (NDA)

20182 events

FDANov 6

Lexette — BRYHALI

Application NDA209355 (NDA)

FDAMay 24

Lexette — LEXETTE

Application NDA210566 (NDA)

20221 event

FDANov 17

Luminal — SEZABY

Application NDA215910 (NDA)

20241 event

FDAJul 25

Leqselvi — LEQSELVI

Application NDA217900 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)